Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch Says B+L Spinout Or IPO Could Occur During ‘October Timeframe’

Executive Summary

During Bausch Health’s first quarter earnings call, CEO Papa said he’ll lead Bausch + Lomb following the corporate split. Overall the company reported flat revenues, but said its pandemic rebound is ongoing.

You may also be interested in...



J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark

Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming, what the year could look like in deals and new updates from multiple Asian companies. 

J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark

Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming and new updates from multiple Asian companies. 

Bausch + Lomb’s Dry Eye Pivotal Data Pave The Way For Spinout

B+L’s novel therapy for a subset of dry eye disease hits both sign and symptom endpoints in the first of two Phase III studies. The product could add value to a planned spinout.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel